Acetyl Gastric Inhibitory Peptide (human) (TFA)

Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity[1][2][3].

Product Specifications

Product Name Alternative

Human N-acetyl GIP (TFA)

UNSPSC

12352209

Target

Insulin Receptor

Type

Peptides

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Endocrinology; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/acetyl-gastric-inhibitory-peptide-human-tfa.html

Purity

99.70

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(C)N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC4=CNC=N4)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC5=CC=CC=C5)C(N[C@@H](C(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC6=CNC7=CC=CC=C67)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC8=CNC9=CC=CC=C89)C(N[C@@H](CCCCN)C(N[C@@H](CC%10=CNC=N%10)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F

Molecular Formula

C228H340N60O67S.C2HF3O2

Molecular Weight

5139.62

References & Citations

[1]O'Harte FP, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002 Sep;45 (9) :1281-91. |[2]Gault Victor A, et al. GIP peptide analogues for treatment of diabetes, insulin resistance and obesity: World Intellectual Property Organization, WO2005082928[P]. 2005-12-01. |[3]O'Harte, et al. Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function: World Intellectual Property Organization, WO2007028632[P].2007-03-15.